Pfizer pulls batches of antibiotic in Australia over anaphylaxis risk

By Gareth Macdonald

- Last updated on GMT


Related tags Active pharmaceutical ingredient Pharmaceutical drug Pharmacology

Pfizer has recalled 10 batches of gentamicin in Australia because of problems with an API supplied by a third party.

Pfizer began the recall this month​ according to the Australian Therapeutic Goods Administration (TGA).

The agency said, “It has been identified that the affected batches of gentamicin injection may contain higher than expected amounts of histamine​.”

"Histamine injected intravenously or intramuscularly can potentially lead to signs and symptoms of hypersensitivity reactions, including severe allergic reaction​," it added.

A Pfizer representative confirmed the recall, telling us, “During a recent internal investigation Pfizer has identified that select batches of Gentamicin Injection BP 80 mg in 2 mL Steriluer may contain higher than expected histamine levels.​”

This is the result of an issue with the active product ingredient provided by a third party supplier​,” she said. The spokesperson declined to name the active pharmaceutical ingredient (API) manufacturer involved.

Pfizer said the recall would not affect the availability of the drug in Australia.

Histamine issues

Gentamicin is a generic version of the injectable antibiotic Garamycin, which was developed by Schering-Plough (which is now owned by Merck & Co).  

It is used to treat serious and potentially life-threatening infections and is on the World Health Organisation’s (WHO) list of essential medicines.

Pfizer is not the only drug firm that has recalled Gentamicin due to problems with the API in recent months.

In July​, Health Canada announced that Novartis’ generics unit Sandoz had pulled 12 batches of its version of the antibiotic.

Sandoz said it had found “histamine contamination in three Active Pharmaceutical Ingredient (API) batches​” used to make its product.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more